skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Polyvalent vaccine approaches to combat HIV-1 diversity

Abstract

In this study, a key unresolved challenge for developing an effective HIV-1 vaccine is the discovery of strategies to elicit immune responses that are able to cross-protect against a significant fraction of the diverse viruses that are circulating worldwide. Here, we summarize some of the immunological implications of HIV-1 diversity, and outline the rationale behind several polyvalent vaccine design strategies that are currently under evaluation. Vaccine-elicited T-cell responses, which contribute to the control of HIV-1 in natural infections, are currently being considered in both prevention and treatment settings. Approaches now in preclinical and human trials include full proteins in novel vectors, concatenated conserved protein regions, and polyvalent strategies that improve coverage of epitope diversity and enhance the cross-reactivity of responses. While many barriers to vaccine induction of broadly neutralizing antibody (bNAb) responses remain, epitope diversification has emerged as both a challenge and an opportunity. Recent longitudinal studies have traced the emergence of bNAbs in HIV-1 infection, inspiring novel approaches to recapitulate and accelerate the events that give rise to potent bNAb in vivo. In this review, we have selected two such lineage-based design strategies to illustrate how such in-depth analysis can offer conceptual improvements that may bring us closer tomore » an effective vaccine.« less

Authors:
 [1]; ORCiD logo [2]; ORCiD logo [2];  [3]
  1. Los Alamos National Lab. (LANL), Los Alamos, NM (United States); New Mexico Consortium, Los Alamos, NM (United States)
  2. Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
  3. Univ. of Pennsylvania, Philadelphia, PA (United States)
Publication Date:
Research Org.:
Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
Sponsoring Org.:
National Institutes of Health (NIH); USDOE
OSTI Identifier:
1346839
Report Number(s):
LA-UR-16-26755
Journal ID: ISSN 0105-2896
Grant/Contract Number:  
AC52-06NA25396
Resource Type:
Journal Article: Accepted Manuscript
Journal Name:
Immunological Reviews
Additional Journal Information:
Journal Volume: 275; Journal Issue: 1; Journal ID: ISSN 0105-2896
Publisher:
Wiley
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; Biological Science; AIDS; antibodies; antigens/peptides/epitopes; B cells; vaccination; viral

Citation Formats

Korber, Bette, Hraber, Peter Thomas, Wagh, Kshitij, and Hahn, Beatrice H. Polyvalent vaccine approaches to combat HIV-1 diversity. United States: N. p., 2017. Web. doi:10.1111/imr.12516.
Korber, Bette, Hraber, Peter Thomas, Wagh, Kshitij, & Hahn, Beatrice H. Polyvalent vaccine approaches to combat HIV-1 diversity. United States. doi:10.1111/imr.12516.
Korber, Bette, Hraber, Peter Thomas, Wagh, Kshitij, and Hahn, Beatrice H. Mon . "Polyvalent vaccine approaches to combat HIV-1 diversity". United States. doi:10.1111/imr.12516. https://www.osti.gov/servlets/purl/1346839.
@article{osti_1346839,
title = {Polyvalent vaccine approaches to combat HIV-1 diversity},
author = {Korber, Bette and Hraber, Peter Thomas and Wagh, Kshitij and Hahn, Beatrice H.},
abstractNote = {In this study, a key unresolved challenge for developing an effective HIV-1 vaccine is the discovery of strategies to elicit immune responses that are able to cross-protect against a significant fraction of the diverse viruses that are circulating worldwide. Here, we summarize some of the immunological implications of HIV-1 diversity, and outline the rationale behind several polyvalent vaccine design strategies that are currently under evaluation. Vaccine-elicited T-cell responses, which contribute to the control of HIV-1 in natural infections, are currently being considered in both prevention and treatment settings. Approaches now in preclinical and human trials include full proteins in novel vectors, concatenated conserved protein regions, and polyvalent strategies that improve coverage of epitope diversity and enhance the cross-reactivity of responses. While many barriers to vaccine induction of broadly neutralizing antibody (bNAb) responses remain, epitope diversification has emerged as both a challenge and an opportunity. Recent longitudinal studies have traced the emergence of bNAbs in HIV-1 infection, inspiring novel approaches to recapitulate and accelerate the events that give rise to potent bNAb in vivo. In this review, we have selected two such lineage-based design strategies to illustrate how such in-depth analysis can offer conceptual improvements that may bring us closer to an effective vaccine.},
doi = {10.1111/imr.12516},
journal = {Immunological Reviews},
number = 1,
volume = 275,
place = {United States},
year = {Mon Jan 30 00:00:00 EST 2017},
month = {Mon Jan 30 00:00:00 EST 2017}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record

Citation Metrics:
Cited by: 3 works
Citation information provided by
Web of Science

Save / Share: